Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients

Author:

de Boni LauraORCID,Wallis Amber,Hays Watson Aurelia,Ruiz-Riquelme AlejandroORCID,Leyland Louise-Ann,Bourinaris Thomas,Hannaway Naomi,Wüllner Ullrich,Peters Oliver,Priller JosefORCID,Falkenburger Björn H,Wiltfang JensORCID,Bähr Mathias,Zerr Inga,Bürger Katharina,Perneczky RobertORCID,Teipel Stefan,Löhle Matthias,Hermann Wiebke,Schott Björn-HendrikORCID,Brockmann Kathrin,Spottke Annika,Haustein Katrin,Breuer Peter,Houlden Henry,Weil Rimona SORCID,Bartels TimORCID

Abstract

AbstractSynucleinopathies such as Parkinson’s disease (PD) are defined by the accumulation and aggregation of the α-synuclein protein in neurons, glia and other tissues. We have previously shown that destabilization of α-synuclein tetramers is associated with familial PD due to SNCA mutations and demonstrated brain-region specific alterations of α-synuclein multimers in sporadic PD patients following the classical Braak spreading theory. In this study, we assessed relative levels of disordered and higher-ordered multimeric forms of cytosolic α-synuclein in blood from familial PD with G51D mutations and sporadic PD patients. We used an adapted in vitro-cross-linking protocol for human EDTA-whole blood. The relative levels of higher-ordered α-synuclein tetramers were diminished in blood from familial PD and sporadic PD patients compared to controls. Interestingly, the relative amount of α-synuclein tetramers was already decreased in asymptomatic G51D carriers, supporting the hypothesis that α-synuclein multimer destabilization precedes the development of clinical PD. Our data, therefore suggest that measuring α-synuclein tetramers in blood may have potential as a facile biomarker assay for early detection and quantitative tracking of PD progression.

Funder

Deutsches Zentrum für Neurodegenerative Erkrankungen

University Bonn

Maria Zambrano Fellowship

Ministerio de Ciencia e Innovación

ERDF

Rosetrees Trust

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

University of Bonn

Wellcome Trust

NIH UK

DRI

Eisei pharmaceuticals

US National Institute of Neurological Disorders

Chan Zuckerberg Collaborative Pairs Initiative Phase 2

UK Dementia Research Institute (DRI), which receives its funding from DRI Ltd., the UK Medical Research Council and Alzheimer’s Society, and Alzheimer’s Research UK.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3